Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application.
BACKGROUND
Erythromycin, a hydrophobic antibiotic used to treat infectious diseases, is now gaining attention because of its anti-inflammatory effects and ability to inhibit osteoclasts formation. The aim of this study was to explore a cyclodextrin-erythromycin (CD-EM) complex for sustained treatment of orthopedic inflammation.


RESULTS
Erythromycin was reacted with β-cyclodextrin to form a nonhost-guest CD-EM complex using both kneading and stirring approaches. Physiochemical measurement data indicated that erythromycin and cyclodextrin formed a packing complex driven by intermolecular forces instead of a host-guest structure due to the limited space in the inner cavity of β-cyclodextrin. The CD-EM complex improved the stability of erythromycin in aqueous solution and had a longer duration of bactericidal activity than free erythromycin. Cytotoxicity and cell differentiation were evaluated in both murine MC3T3 preosteoblast cells and RAW 264.7 murine macrophage cells. The CD-EM complex was noncytotoxic and showed significant inhibition of osteoclast formation but had little effect on osteoblast viability and differentiation.


CONCLUSIONS
These attributes are especially important for the delivery of an adequate amount of erythromycin to the site of periprosthetic inflammation and reducing local inflammation in a sustained manner.
Department of Biomedical Engineering, Wayne State University, Detroit, MI 48201, USA.
Wei
W
Song
Xiaowei
X
Yu
Sunxi
S
Wang
Ralph
R
Blasier
David C
DC
Markel
Guangzhao
G
Mao
Tong
T
Shi
Weiping
W
Ren
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry; D017209:Apoptosis / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D003505:Cyclodextrins / Q000008:administration & dosage* / Q000737:chemistry; D004359:Drug Therapy, Combination / Q000379:methods; D004917:Erythromycin / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D003505:Cyclodextrins; D053769:Nanocapsules; D004917:Erythromycin